<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02012322</url>
  </required_header>
  <id_info>
    <org_study_id>R34AG026338-01</org_study_id>
    <secondary_id>R34AG026338-01</secondary_id>
    <nct_id>NCT02012322</nct_id>
  </id_info>
  <brief_title>UCSD Q10 and Aging Study</brief_title>
  <official_title>Coenzyme Q10 and Aging: A Planning Grant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Goal: The investigators propose to test the feasibility of giving the supplement coenzyme Q10
      (Q10) improves symptoms and subjective health in an aging population.

      Rationale: Direct empirical evidence has supported benefit of Q10 to many symptoms such as
      fatigue, muscle pain, and cognition. In addition, Q10 has also been reported to benefit other
      symptoms including headaches, sleep disturbances, and breathing problems. This provides a
      strong rationale for testing whether Q10 will have similar benefit to these symptoms in an
      aging population.

      Method: 44 aging subjects will participate. The design is a 9 month, randomized,
      double-blind, placebo-controlled crossover study. Each subject will be &quot;crossed over&quot; between
      high dose Q10 (300mg), low dose Q10 (100mg), and placebo, receiving each agent for 3 month
      periods. Neither subjects nor investigators will know which substance each subject is
      receiving in which phase. Subjects will be randomly assigned to one of six arms.

      Assessments: Assessments will include feasibility of study, subjective quality of life,
      energy, and metabolic and lipid panels. Analyses will show whether Q10 led to improvements
      when compared to placebo; whether higher Q10 doses improved outcomes more than lower doses;
      and whether people with certain symptoms or characteristics get more benefit than people with
      other symptoms or characteristics.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Goal: To determine feasibility of a double-blind placebo-controlled crossover study to test
      whether coenzyme Q10 (Q10) administration reduces symptoms and improve subjective health in
      an aging population.

      Rationale: In a number of settings, studies have reported benefits of Q10 to fatigue, muscle
      pain, and cognition. Additionally Q10 defends against mechanisms that may play a role in
      health problems in aging populations. For these reasons, a study evaluating benefits by Q10
      to symptoms and quality of life in an aging population is merited.

      Subjects: 44 subjects ages 55 and older.

      Design: 9 month, randomized, placebo-controlled, double-blind crossover study.

      Analyses: Nonparametric and secondarily parametric analyses will compare effects of Q10 vs
      placebo; and of higher dose vs lower dose Q10 on primary and secondary endpoints. Possible
      effect modification (differential benefit) based on factors such as oxidative state and Q10
      serum concentration will be explored through regression analysis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility and Acceptability (e.g., duration of study, study visits, comprehension of the quality of life questionnaires, reliability of the cognitive function measures, tolerance of study drug)</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Energy (self-reported)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic and Lipid Panel</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Age Related Symptoms</condition>
  <condition>Age Related Quality of Life Issues</condition>
  <arm_group>
    <arm_group_label>Placebo vs. Q10 100mg vs. Q10 300mg</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo vs. Q10 300mg vs. Q10 100mg</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Q10 100mg vs. Placebo vs. Q10 300mg</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Q10 100mg vs. Q10 300mg vs. Placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Q10 300mg vs. Placebo vs. Q10 100mg</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Q10 300mg vs. Q10 100mg vs. Placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Coenzyme Q10</intervention_name>
    <description>100mg/day for three months</description>
    <arm_group_label>Placebo vs. Q10 100mg vs. Q10 300mg</arm_group_label>
    <arm_group_label>Placebo vs. Q10 300mg vs. Q10 100mg</arm_group_label>
    <arm_group_label>Q10 100mg vs. Placebo vs. Q10 300mg</arm_group_label>
    <arm_group_label>Q10 100mg vs. Q10 300mg vs. Placebo</arm_group_label>
    <arm_group_label>Q10 300mg vs. Placebo vs. Q10 100mg</arm_group_label>
    <arm_group_label>Q10 300mg vs. Q10 100mg vs. Placebo</arm_group_label>
    <other_name>PharmaNord Myoquinione softgel caplets</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Coenzyme Q10</intervention_name>
    <description>300mg/day for three months</description>
    <arm_group_label>Placebo vs. Q10 100mg vs. Q10 300mg</arm_group_label>
    <arm_group_label>Placebo vs. Q10 300mg vs. Q10 100mg</arm_group_label>
    <arm_group_label>Q10 100mg vs. Placebo vs. Q10 300mg</arm_group_label>
    <arm_group_label>Q10 100mg vs. Q10 300mg vs. Placebo</arm_group_label>
    <arm_group_label>Q10 300mg vs. Placebo vs. Q10 100mg</arm_group_label>
    <arm_group_label>Q10 300mg vs. Q10 100mg vs. Placebo</arm_group_label>
    <other_name>PharmaNord Myoquinione softgel caplets</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Three month period</description>
    <arm_group_label>Placebo vs. Q10 100mg vs. Q10 300mg</arm_group_label>
    <arm_group_label>Placebo vs. Q10 300mg vs. Q10 100mg</arm_group_label>
    <arm_group_label>Q10 100mg vs. Placebo vs. Q10 300mg</arm_group_label>
    <arm_group_label>Q10 100mg vs. Q10 300mg vs. Placebo</arm_group_label>
    <arm_group_label>Q10 300mg vs. Placebo vs. Q10 100mg</arm_group_label>
    <arm_group_label>Q10 300mg vs. Q10 100mg vs. Placebo</arm_group_label>
    <other_name>PharmaNord matched identical softgel placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females &gt;55 years with a minimum of 40% females

          -  Willing to fast for 8 hrs prior to blood draw

          -  Must be able to complete survey instruments or assessments

          -  Must be independent living

          -  Must be community living

          -  Willing to defer participation in other clinical trials till after completion of study
             participation.

          -  Agree to abstain from other Q10-containing products for the duration of participation

        Exclusion Criteria:

          -  Women who are pre-menopausal or have the capability to conceive children

          -  Diagnosed with HIV

          -  Diagnosed with cancer (except non-melanoma skin cancer)

          -  Diagnosed with NYHA Stage 3 or 4 congestive heart failure

          -  Is currently taking coumadin

          -  Cannot commit to continued participation for a minimum of 1 year

          -  Have taken Q10 including dermal preparations in the last three months

          -  Due to the very small number of subjects, special classes (including prisoners,
             institutionalized individuals, or other who may be considered vulnerable populations)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Beatrice A Golomb, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Diego</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSD General Clinical Research Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.cnl.salk.edu/~bgolomb/</url>
    <description>Beatrice Golomb MD, PhD CURRICULUM VITAE</description>
  </link>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 10, 2013</study_first_submitted>
  <study_first_submitted_qc>December 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2013</study_first_posted>
  <last_update_submitted>December 17, 2013</last_update_submitted>
  <last_update_submitted_qc>December 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Diego</investigator_affiliation>
    <investigator_full_name>Beatrice Golomb</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Aging</keyword>
  <keyword>Coenzyme Q10</keyword>
  <keyword>Q10</keyword>
  <keyword>Quality of Life</keyword>
  <keyword>Oxidative Stress</keyword>
  <keyword>Mitochondrial Function</keyword>
  <keyword>Cell Energetics</keyword>
  <keyword>Fatigue</keyword>
  <keyword>Ubiquinone</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coenzyme Q10</mesh_term>
    <mesh_term>Ubiquinone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

